Urology Times is pleased to announce the appointment of Stacy Loeb, MD, MSc, to its Editorial Council, representing the areas of men’s health and prostate cancer.
Dr. LoebUrology Times is pleased to announce the appointment of Stacy Loeb, MD, MSc, to its Editorial Council, representing the areas of men’s health and prostate cancer.
Dr. Loeb is assistant professor of urology and population health at New York University School of Medicine, New York. An international leader in the field of prostate cancer, Dr. Loeb is the author of more than 200 published peer-reviewed articles and eight book chapters. She has a K07 grant from the National Cancer Institute to study active surveillance for prostate cancer.
She hosts the “Men’s Health Show” on Sirius XM 81 satellite radio and is active on Twitter using the handle @LoebStacy.
Dr. Loeb received her medical degree from Northwestern Feinberg School of Medicine, Chicago and completed her residency at Johns Hopkins University, Baltimore.
Twitter’s benefits extend beyond ‘social’ aspects
Study appears to refute obesity paradox in kidney cancer
CNS may be path to future voiding dysfunction therapies
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Dr. Goudelocke outlines stand-up urgency in patients with OAB
April 18th 2024"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.